News
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Zacks.com on MSN9h
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
MarketBeat on MSN4h
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...
Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...
The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...
Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...
Merck recently declared a Q4 dividend of $0.81 per share while also securing Health Canada's nod for KEYTRUDA® in cervical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback